デフォルト表紙
市場調査レポート
商品コード
1020361

視神経脊髄炎(デビック症候群)の世界市場(2021年~2028年)

Global Neuromyelitis Optica (Devic's Syndrome) Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
視神経脊髄炎(デビック症候群)の世界市場(2021年~2028年)
出版日: 2021年07月28日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

デビック病として知られる視神経脊髄炎スペクトラム障害(NMOSD)は、視神経の炎症(視神経炎)と脊髄の炎症(脊髄炎)を主症状とする脳と脊髄の慢性疾患です。

当レポートは、世界の視神経脊髄炎(デビック症候群)市場について調査しており、市場規模、機会や影響、成長および抑制要因、COVID-19による影響、製品タイプ・用途・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 視神経脊髄炎(デビック症候群)市場調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 視神経脊髄炎(デビック症候群)市場-市場定義と概要

第3章 視神経脊髄炎(デビック症候群)市場-エグゼクティブサマリー

  • 製品タイプの市場内訳
  • 用途別の市場内訳

第4章 視神経脊髄炎(デビック症候群)市場-市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 視神経脊髄炎(デビック症候群)市場-業界分析

  • ポーターのファイブフォース分析
  • 疫学分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 視神経脊髄炎(デビック症候群)市場-COVID-19分析

  • 市場でのCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以後または今後のシナリオ
  • Covid-19における価格動向
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 視神経脊髄炎(デビック症候群)市場-製品タイプ

  • イントロダクション
    • 市場規模分析および前年比成長分析
    • 市場魅力指数
  • エクリズマブ
  • メチルプレドニゾロン
  • アザチオプリン
  • ミコフェノール酸モフェチル
  • リツキシマブ

第8章 視神経脊髄炎(デビック症候群)市場-アプリケーション別

  • イントロダクション
    • 市場規模分析および前年比成長分析
    • 市場魅力指数
  • 病院
  • クリニック
  • 在宅医療と遠隔医療

第9章 視神経脊髄炎(デビック症候群)市場-地域別

  • イントロダクション
    • 市場規模分析(2018-2028)、および前年比成長分析(2020-2028)
    • 市場魅力指数
  • 北米
    • イントロダクション
    • 主要地域別の力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 用途別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要地域別の力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 用途別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要地域別の力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 用途別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要地域別の力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 用途別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要地域別の力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 用途別:市場規模分析、および前年比成長分析

第10章 視神経脊髄炎(デビック症候群)市場-競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業のリスト
  • 革新的技術を持つ企業のリスト
  • スタートアップ企業のリスト

第11章 視神経脊髄炎(デビック症候群)市場-企業プロファイル

  • Alexion Pharmaceuticals, Inc
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Hoffmann-La Roche Ltd
  • Viela Bio
  • Genentech, Inc
  • AstraZeneca
  • Shanghai Pharmaceutical Group Co., Ltd.
  • China Resources Pharmaceutical GroupCo.,Ltd.
  • Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
  • SAGENT PHARMACEUTICALS, INC.
  • ZYDUS PHARMACEUTICALS, INC.

第12章 視神経脊髄炎(デビック症候群)市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMMD3680

Neuromyelitis Optica (Devic's Syndrome) Market. Overview

The Neuromyelitis Optica (Devic's Syndrome) Market. The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Neuromyelitis optica spectrum disorder (NMOSD) ,known as Devic disease, is a chronic disorder of the brain and spinal cord which is dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Neuromyelitis Optica (Devic's Syndrome) Market. Dynamics

An increase in neuromyelitis optica (Devic's syndrome ) incidence will drive the market. Morever increase in research and development by key players will see a rise in its market.

An increase in neuromyelitis optica (Devic's syndrome ) incidence will drive the market

Neuromyelitis optica or NMO is also called devic's disease , is an immunological disorder. It is often characterized by immune attacks on the optic nerves (which transmit what you see to your brain) and the spinal cord. The FDA recently approved two drugs to treat it. Eculizumab (Soliris), inebilizumab-cdon (Uplizna), and satralizumab-mwge (Enspryng) they work by targeting the defective antibodies that attack the healthy cells in your body, triggering NMO. A doctor may prescribe other drugs to suppress the immune system.

NMOSD occurs in individuals of all races. Its prevalence is approximately 1-10 per 100,000 individuals. Though somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry, it seems to be similar worldwide.

An increase in research and development will increase the market in the forecast period

In recent years, scientists and clinical neurologists have gained enormous interest in the condition, fuelled by detecting a specific serum immunoglobulin (Ig)G reactivity (NMO-IgG) in up to 80% of patients with NMO. These autoantibodies were later shown to target aquaporin-4 (AQP4), the most abundant water channel in the central nervous system (CNS).

The U.S. FDA has approved Soliris (eculizumab) injection in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive for intravenous use. NMOSD is an autoimmune disease of the CNS that affects the optic nerves and spinal cord. Soliris provided the first FDA-approved treatment for neuromyelitis optica spectrum disorder, a debilitating disease.

Genentech Inc. for Enspryng (satralizumab-mwge) is approved as a treatment for the rare autoimmune condition neuromyelitis optica spectrum disorder (NMOSD) by the U.S. Drug and Food Administration.

Unavailability of disease specific treatment will hamper the market

Neuromyelitis Optica (Devic's Syndrome) is a relatively rare disease, there are have been no large-scale studies of treatment for this disease. Treatment for an acute attack of Devic's begins with intravenous steroids and is then followed by oral steroids. Incase the steroids are not effective, a treatment known as plasmapheresis is generally used. This therapy cleans the antibodies from the blood by circulating them through a machine, similar to how dialysis works. This disease does not appear to respond to standard medications for multiple sclerosis. There is no cure, but their medicines and treatments may inhibit future disease flares.Patients with neuromyelitis optica (NMO) patients have a 91% to 98% five-year survival rate. Current research indicates that neuromyelitis optica (NMO) patients have a 91% to 98% five-year survival rate.

COVID-19 Impact Analysis

COVID-19 has impacted the healthcare sector and also has a notable impact on the neuromyelitis optica (Devic's Syndrome) market. The admissions due to neuromyelitis optica (Devic's Syndrome) have gone down with increasing demand for COVID-19 treatment in hospitals, and even pharmaceutical companies' interest was more in the development of vaccines for COVID-19. Hence the market was affected by COVID-19.

Neuromyelitis Optica (Devic's Syndrome) Market. Segment Analysis

Eculizumab will dominate this segment of the market

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the CNS distinct from multiple sclerosis and typically presents with a relapsing course of optic neuritis, myelitis and midline brain inflammatory lesions. In at least two-thirds of cases, antibodies against the water channel AQP4 can be found, leading to an antibody-mediated activation of the complement system with consecutive damage to neuronal structures. Eculizumab, a humanized monoclonal antibody against the terminal complement component 5, was shown to significantly reduce the risk of NMOSD relapse in Phase III placebo-controlled trial. Based on this, eculizumab (Soliris®) was the first drug to be formally approved to treat anti-AQP4antibody-positive NMOSD in 2019.

The U.S. FDA has approved Soliris (eculizumab) injection for intravenous use in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients with anti-aquaporin-4 (AQP4) antibody positive.

The hospital segment will dominate the market

Treatment for NMO generally consists of two parts: addressing current attack and preventing the future attacks. During the initial attack, healthcare team will try to get the condition and its symptoms under control. Treatment at this stage is often intravenous corticosteroids and plasma exchange (PLEX).

More than 90% of patients with NMO experience more than one attack, with the attacks being usually severe. Doctors typically recommend ongoing treatment to help prevent future attacks and disease progression. This usually involves immunotherapy, which is a type of treatment that modulates the immune system. The patient should be assisted by doctors during this treatment, and hospitals provide a better facility for the treatment.

Neuromyelitis Optica (Devic's Syndrome) Market. Geographical Analysis

North America will dominate neuromyelitis optica (Devic's Syndrome) market in the forecast period

Increased incidence of neuromyelitis optica (Devic's Syndrome) and major key players in this region will drive the market.

There are approximately 1,000 to 3,000 Canadians living with NMOSD, with the disease being most commonly diagnosed among non-Caucasian women in their 20s to 40s. People with NMOSD experience unpredictable, severe relapses causing cumulative, permanent neurological damage and disability.

The U.S. Drug and Food Administration has approved Genentech Inc. for Enspryng (satralizumab-mwge). AR 50% of patients with NMOSD have permanent visual impairment and paralysis. In the U.S, it is thought to affect approximately 4,000-8,000 Americans.

Neuromyelitis Optica (Devic's Syndrome) Market. Competitive Landscape

Some prominent key players in this market are Alexion Pharmaceuticals, Inc., Hoffmann-La Roche Ltd, Viela Bio, Genentech, Inc., AstraZeneca, Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. SAGENT PHARMACEUTICALS, INC. and ZYDUS PHARMACEUTICALS, INC.

Neuromyelitis Optica (Devic's Syndrome) Market. Key Companies to Watch

Alexion Pharmaceuticals, Inc

Overview: Alexion Pharmaceuticals Inc best known for its development of Soliris, is an American pharmaceutical company which developed a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. It is also involved in immune system research related to autoimmune diseases.

Product Portfolio: The company's mission is to transform the lives of people living with rare diseases,devastating conditions through the development , delivery of innovative medicine, supportive technologies, and healthcare services.

Key Development: On Jun. 27, 2019, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that the U.S. FDA has approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with anti-aquaporin-4 (AQP4) antibody positive.1 Approximately three-quarters (73%) of all patients with NMOSD test positive for anti-AQP4 auto-antibodies.2 The FDA approved SOLIRIS following an expedited six-month priority review.

Why Purchase the Report?

  • Visualize the composition of the neuromyelitis optica (Devic's Syndrome) market. Segmentation By Product Type and By Application highlighting the key commercial assets and players.
  • Identify commercial opportunities in neuromyelitis optica (Devic's Syndrome) market. by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of neuromyelitis optica (Devic's Syndrome) market. - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The neuromyelitis optica (Devic's Syndrome) market. report would provide an access to an approx. 52 market data table, 43 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Neuromyelitis Optica (Devic's Syndrome) Market. - By Product Type

  • Eculizumab
  • Methylprednisolone
  • Azathioprine
  • Mycophenolate Mofetil
  • Rituximab

Neuromyelitis Optica (Devic's Syndrome) Market. - By Application

  • Hospitals
  • Clinic
  • Others

Neuromyelitis Optica (Devic's Syndrome) Market. - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Neuromyelitis Optica (Devic's Syndrome) Market. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Neuromyelitis Optica (Devic's Syndrome) Market. - Market Definition and Overview

3. Neuromyelitis Optica (Devic's Syndrome) Market. - Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet By Application

4. Neuromyelitis Optica (Devic's Syndrome) Market. - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. An increase in neuromyelitis optica (Devic's syndrome ) incidence will drive the market
      • 4.1.1.2. An increase in research and development will increase the market in the forecast period
    • 4.1.2. Restraints:
      • 4.1.2.1. The unavailability of disease-specific treatment will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Neuromyelitis Optica (Devic's Syndrome) Market. - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Neuromyelitis Optica (Devic's Syndrome) Market. - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Neuromyelitis Optica (Devic's Syndrome) Market. - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Eculizumab*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Methylprednisolone
  • 7.4. Azathioprine
  • 7.5. Mycophenolate Mofetil
  • 7.6. Rituximab

8. Neuromyelitis Optica (Devic's Syndrome) Market. - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Clinics
  • 8.4. Homecare and Telemedicine

9. Neuromyelitis Optica (Devic's Syndrome) Market. - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Neuromyelitis Optica (Devic's Syndrome) Market. - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Neuromyelitis Optica (Devic's Syndrome) Market. - Company Profiles

  • 11.1. Alexion Pharmaceuticals, Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Hoffmann-La Roche Ltd
  • 11.3. Viela Bio
  • 11.4. Genentech, Inc
  • 11.5. AstraZeneca
  • 11.6. Shanghai Pharmaceutical Group Co., Ltd.
  • 11.7. China Resources Pharmaceutical GroupCo.,Ltd.
  • 11.8. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
  • 11.9. SAGENT PHARMACEUTICALS, INC.
  • 11.10. ZYDUS PHARMACEUTICALS, INC.

LIST NOT EXHAUSTIVE

12. Neuromyelitis Optica (Devic's Syndrome) Market. - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us